HRP980532B1 - Novel crystalline torasemide modification - Google Patents

Novel crystalline torasemide modification

Info

Publication number
HRP980532B1
HRP980532B1 HR980532A HRP980532A HRP980532B1 HR P980532 B1 HRP980532 B1 HR P980532B1 HR 980532 A HR980532 A HR 980532A HR P980532 A HRP980532 A HR P980532A HR P980532 B1 HRP980532 B1 HR P980532B1
Authority
HR
Croatia
Prior art keywords
torasemide
new
preparation
modification
form iii
Prior art date
Application number
HR980532A
Other languages
English (en)
Inventor
Fili Darko
Dumi� Miljenko
Danilovski Aleksandar
Klepi� Bo�ena
Fistri� Ines
Ore�i� Marina
Horvat-Mikul�i� Jasna
Original Assignee
Pliva
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10946825&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP980532(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pliva filed Critical Pliva
Priority to HR980532A priority Critical patent/HRP980532B1/xx
Priority to AU62240/99A priority patent/AU759291B2/en
Priority to BR9915018-2A priority patent/BR9915018A/pt
Priority to ES99949272T priority patent/ES2237158T3/es
Priority to KR10-2001-7004079A priority patent/KR100437307B1/ko
Priority to DE29924789U priority patent/DE29924789U1/de
Priority to SK423-2001A priority patent/SK4232001A3/sk
Priority to PCT/HR1999/000023 priority patent/WO2000020395A1/en
Priority to DK99949272T priority patent/DK1117643T3/da
Priority to NZ510898A priority patent/NZ510898A/xx
Priority to DE69922977T priority patent/DE69922977C5/de
Priority to AT99949272T priority patent/ATE286024T1/de
Priority to HU0104009A priority patent/HUP0104009A3/hu
Priority to PL99346975A priority patent/PL346975A1/xx
Priority to JP2000574512A priority patent/JP2002526532A/ja
Priority to CA002345789A priority patent/CA2345789A1/en
Priority to IDW20010958A priority patent/ID29931A/id
Priority to PT99949272T priority patent/PT1117643E/pt
Priority to IL14215099A priority patent/IL142150A0/xx
Priority to CN99811710A priority patent/CN1125049C/zh
Priority to EP99949272A priority patent/EP1117643B1/en
Priority to EEP200100194A priority patent/EE04341B1/xx
Priority to ZA200102451A priority patent/ZA200102451B/en
Priority to CZ20011031A priority patent/CZ20011031A3/cs
Priority to TR2001/00909T priority patent/TR200100909T2/xx
Priority to YU24001A priority patent/YU24001A/sh
Priority to SI9930744T priority patent/SI1117643T1/xx
Priority to RU2001111831/04A priority patent/RU2210569C2/ru
Priority to UA2001031966A priority patent/UA72895C2/uk
Priority to US09/434,439 priority patent/US6399637B1/en
Publication of HRP980532A2 publication Critical patent/HRP980532A2/hr
Priority to NO20011633A priority patent/NO317107B1/no
Priority to BG105485A priority patent/BG105485A/xx
Priority to US10/096,277 priority patent/US6833379B2/en
Priority to HK02102011.9A priority patent/HK1040250B/zh
Priority to US10/871,667 priority patent/US20040229919A1/en
Publication of HRP980532B1 publication Critical patent/HRP980532B1/xx
Priority to US11/357,109 priority patent/US20060205951A1/en
Priority to US11/822,274 priority patent/US20070276015A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/53—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms
    • C07D213/71—Sulfur atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Liquid Crystal (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Liquid Crystal Substances (AREA)
HR980532A 1998-02-10 1998-10-02 Novel crystalline torasemide modification HRP980532B1 (en)

Priority Applications (37)

Application Number Priority Date Filing Date Title
HR980532A HRP980532B1 (en) 1998-10-02 1998-10-02 Novel crystalline torasemide modification
EP99949272A EP1117643B1 (en) 1998-10-02 1999-10-01 New crystal modification n of torasemide
IL14215099A IL142150A0 (en) 1998-10-02 1999-10-01 New crystal modification iii of torasemide
UA2001031966A UA72895C2 (uk) 1998-10-02 1999-10-01 Нова кристалічна модифікація n торасеміду
ES99949272T ES2237158T3 (es) 1998-10-02 1999-10-01 Nueva modificcion cristalina n de torasemida.
KR10-2001-7004079A KR100437307B1 (ko) 1998-10-02 1999-10-01 토라세미드의 새로운 결정 변형태 ⅲ
DE29924789U DE29924789U1 (de) 1998-10-02 1999-10-01 Neue Kristallmodifikation N von Torasemid
SK423-2001A SK4232001A3 (en) 1998-10-02 1999-10-01 New crystal modification iii of torasemide
PCT/HR1999/000023 WO2000020395A1 (en) 1998-10-02 1999-10-01 New crystal modification iii of torasemide
DK99949272T DK1117643T3 (da) 1998-10-02 1999-10-01 Ny krystalmodifikation N af torasemid
CN99811710A CN1125049C (zh) 1998-10-02 1999-10-01 托拉沙得新晶体变型n
DE69922977T DE69922977C5 (de) 1998-10-02 1999-10-01 Neue Kristallmodifikation von Torasemid
AT99949272T ATE286024T1 (de) 1998-10-02 1999-10-01 Neue kristallmodifikation n von torasemid
HU0104009A HUP0104009A3 (en) 1998-10-02 1999-10-01 New crystal modification of torasemide, process for its preparation, its use as a ran material and pharmaceutical compositions containing it
PL99346975A PL346975A1 (en) 1998-10-02 1999-10-01 New crystal modification iii of torasemide
JP2000574512A JP2002526532A (ja) 1998-10-02 1999-10-01 トラセミドの新規な結晶変態ｎ型
CA002345789A CA2345789A1 (en) 1998-10-02 1999-10-01 New crystal modification iii of torasemide
BR9915018-2A BR9915018A (pt) 1998-10-02 1999-10-01 Modificação de cristal da torasemida
PT99949272T PT1117643E (pt) 1998-10-02 1999-10-01 Nova modificacao n cristalina de torasemida
AU62240/99A AU759291B2 (en) 1998-10-02 1999-10-01 New crystal modification N of torasemide
NZ510898A NZ510898A (en) 1998-10-02 1999-10-01 Crystal modification N of torasemide
IDW20010958A ID29931A (id) 1998-10-02 1999-10-01 Modifikasi kristal torasemida
SI9930744T SI1117643T1 (en) 1998-10-02 1999-10-01 New crystal modification n of torasemide
ZA200102451A ZA200102451B (en) 1998-10-02 1999-10-01 New crystal modification III of torasemide.
CZ20011031A CZ20011031A3 (cs) 1998-10-02 1999-10-01 Nová krystalová modifikace torasemidu
TR2001/00909T TR200100909T2 (tr) 1998-10-02 1999-10-01 Torasemid'in yeni kristal modifikasyonu.
YU24001A YU24001A (sh) 1998-10-02 1999-10-01 Nova kristalna modifikacija torasemida
EEP200100194A EE04341B1 (et) 1998-10-02 1999-10-01 Torasemiidi kristallmodifikatsioon N, selle valmistamismeetod, kasutamine ja ravimvorm
RU2001111831/04A RU2210569C2 (ru) 1998-10-02 1999-10-01 Кристаллическая модификация n-тораземида, способ ее получения, фармацевтическая форма
US09/434,439 US6399637B1 (en) 1998-02-10 1999-11-05 Crystal modification of torasemide
NO20011633A NO317107B1 (no) 1998-10-02 2001-03-30 Ny krystallmodifikasjon av torasemid, fremgangsmate for fremstilling derav, samt farmasoytisk preparat
BG105485A BG105485A (en) 1998-10-02 2001-05-02 New crystal modification n of torasemide
US10/096,277 US6833379B2 (en) 1998-10-02 2002-03-13 Crystal modification of torasemide
HK02102011.9A HK1040250B (zh) 1998-10-02 2002-03-15 托拉沙得新晶體變型n
US10/871,667 US20040229919A1 (en) 1998-10-02 2004-06-21 Crystal modification of torasemide
US11/357,109 US20060205951A1 (en) 1998-10-02 2006-02-21 New crystal modification of torasemide
US11/822,274 US20070276015A1 (en) 1998-10-02 2007-07-03 Crystal modification of torasemide

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
HR980532A HRP980532B1 (en) 1998-10-02 1998-10-02 Novel crystalline torasemide modification

Publications (2)

Publication Number Publication Date
HRP980532A2 HRP980532A2 (en) 2000-12-31
HRP980532B1 true HRP980532B1 (en) 2005-06-30

Family

ID=10946825

Family Applications (1)

Application Number Title Priority Date Filing Date
HR980532A HRP980532B1 (en) 1998-02-10 1998-10-02 Novel crystalline torasemide modification

Country Status (32)

Country Link
US (5) US6399637B1 (pt)
EP (1) EP1117643B1 (pt)
JP (1) JP2002526532A (pt)
KR (1) KR100437307B1 (pt)
CN (1) CN1125049C (pt)
AT (1) ATE286024T1 (pt)
AU (1) AU759291B2 (pt)
BG (1) BG105485A (pt)
BR (1) BR9915018A (pt)
CA (1) CA2345789A1 (pt)
CZ (1) CZ20011031A3 (pt)
DE (2) DE29924789U1 (pt)
DK (1) DK1117643T3 (pt)
EE (1) EE04341B1 (pt)
ES (1) ES2237158T3 (pt)
HK (1) HK1040250B (pt)
HR (1) HRP980532B1 (pt)
HU (1) HUP0104009A3 (pt)
ID (1) ID29931A (pt)
IL (1) IL142150A0 (pt)
NO (1) NO317107B1 (pt)
NZ (1) NZ510898A (pt)
PL (1) PL346975A1 (pt)
PT (1) PT1117643E (pt)
RU (1) RU2210569C2 (pt)
SI (1) SI1117643T1 (pt)
SK (1) SK4232001A3 (pt)
TR (1) TR200100909T2 (pt)
UA (1) UA72895C2 (pt)
WO (1) WO2000020395A1 (pt)
YU (1) YU24001A (pt)
ZA (1) ZA200102451B (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6394707B1 (en) 1997-05-08 2002-05-28 Jack Kennedy Metal Products & Buildings, Inc. Yieldable mine roof support
HRP980532B1 (en) 1998-10-02 2005-06-30 Pliva Novel crystalline torasemide modification
JP2003527319A (ja) * 1999-08-11 2003-09-16 テバ ファーマシューティカル インダストリーズ リミティド トルセミド多形体
DE10013289A1 (de) * 2000-03-17 2001-09-20 Knoll Ag Torasemid enthaltende pharmazeutische Zubereitungen
HRP20000162B1 (en) 2000-03-20 2004-06-30 Pliva D D Amorphous torasemide modification
HRP20000328A2 (en) * 2000-05-19 2002-02-28 Pliva Farmaceutska Ind Dionik Novel polymorph v of torasemide
IN192178B (pt) 2001-08-03 2004-03-06 Ranbaxy Lab
HRP20020603B1 (en) * 2002-07-19 2008-11-30 Pliva D.D. New process for the preparation of modification i n-(1-methylethylaminocarbonyl)-4-(3-methylphenylamino)-3-pyridinesulfonamide
CA2424644A1 (en) * 2003-04-07 2004-10-07 David John Mckenzie Preparation of torasemide
US20050065183A1 (en) * 2003-07-31 2005-03-24 Indranil Nandi Fexofenadine composition and process for preparing
PL1750862T3 (pl) * 2004-06-04 2011-06-30 Teva Pharma Kompozycja farmaceutyczna zawierająca irbesartan
JP4406845B2 (ja) 2007-02-20 2010-02-03 トヨタ自動車株式会社 二次電池電極材の剥離剤及び該剥離剤を用いた二次電池の処理方法
EP2705843A1 (en) * 2012-09-05 2014-03-12 Pharnext Therapeutic approaches for treating epilepsy and related disorders through reduction of epileptogenesis
CN104370805B (zh) * 2013-08-13 2016-09-07 天津汉瑞药业有限公司 托拉塞米化合物
CN106038500A (zh) * 2016-05-26 2016-10-26 南京正科医药股份有限公司 一种托拉塞米片
CN115417810B (zh) * 2022-09-22 2023-10-10 南京正科医药股份有限公司 一种托拉塞米晶型ⅰ的精制方法
CN117486789A (zh) * 2023-12-29 2024-02-02 江西中医药大学 一种托拉塞米共晶盐及其制备方法和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1477664A (en) * 1974-04-17 1977-06-22 Christiaens Sa A Pyridine derivatives
US4055650A (en) * 1974-04-17 1977-10-25 A. Christiaens Societe Anonyme Certain 4-phenoxy(or phenylthio)-3-n-acylated-sulfonamido-pyridines
US4473693A (en) 1978-08-04 1984-09-25 Stewart Walter W Aminonaphthalimide dyes for intracellular labelling
DE3529529A1 (de) * 1985-08-17 1987-02-19 Boehringer Mannheim Gmbh Verfahren zur herstellung einer stabilen modifikation von torasemid
US6166041A (en) * 1995-10-11 2000-12-26 Euro-Celtique, S.A. 2-heteroaryl and 2-heterocyclic benzoxazoles as PDE IV inhibitors for the treatment of asthma
HRP980532B1 (en) 1998-10-02 2005-06-30 Pliva Novel crystalline torasemide modification
US5914336A (en) * 1998-06-02 1999-06-22 Boehringer Mannheim Gmbh Method of controlling the serum solubility of orally administered torasemide and composition relating thereto
US6166045A (en) * 1998-06-02 2000-12-26 Roche Diagnostics Gmbh Torasemide of modification III

Also Published As

Publication number Publication date
HUP0104009A2 (hu) 2002-02-28
KR20010079962A (ko) 2001-08-22
ES2237158T3 (es) 2005-07-16
TR200100909T2 (tr) 2001-07-23
PL346975A1 (en) 2002-03-11
AU6224099A (en) 2000-04-26
US20070276015A1 (en) 2007-11-29
JP2002526532A (ja) 2002-08-20
EP1117643B1 (en) 2004-12-29
PT1117643E (pt) 2005-05-31
DE69922977C5 (de) 2008-12-24
YU24001A (sh) 2003-02-28
HUP0104009A3 (en) 2002-04-29
CN1321149A (zh) 2001-11-07
ZA200102451B (en) 2001-09-28
DE69922977T2 (de) 2005-12-08
EP1117643A1 (en) 2001-07-25
ATE286024T1 (de) 2005-01-15
WO2000020395A1 (en) 2000-04-13
DE69922977D1 (de) 2005-02-03
UA72895C2 (uk) 2005-05-16
CZ20011031A3 (cs) 2001-08-15
SI1117643T1 (en) 2005-06-30
AU759291B2 (en) 2003-04-10
EE200100194A (et) 2002-06-17
US20040229919A1 (en) 2004-11-18
CA2345789A1 (en) 2000-04-13
HRP980532A2 (en) 2000-12-31
DK1117643T3 (da) 2005-03-29
RU2210569C2 (ru) 2003-08-20
US20030055258A2 (en) 2003-03-20
NO317107B1 (no) 2004-08-09
US6833379B2 (en) 2004-12-21
NO20011633D0 (no) 2001-03-30
HK1040250A1 (en) 2002-05-31
CN1125049C (zh) 2003-10-22
BG105485A (en) 2002-01-31
KR100437307B1 (ko) 2004-06-25
SK4232001A3 (en) 2001-10-08
HK1040250B (zh) 2004-03-05
ID29931A (id) 2001-10-25
BR9915018A (pt) 2001-08-14
US20020147346A1 (en) 2002-10-10
NZ510898A (en) 2002-10-25
IL142150A0 (en) 2002-03-10
US6399637B1 (en) 2002-06-04
DE29924789U1 (de) 2005-08-25
US20060205951A1 (en) 2006-09-14
NO20011633L (no) 2001-03-30
EE04341B1 (et) 2004-08-16

Similar Documents

Publication Publication Date Title
HRP980532B1 (en) Novel crystalline torasemide modification
CA2360557A1 (en) Biodegradable and thermosensitive polyphosphazenes and their preparation method
ES8204484A1 (es) Un procedimiento de preparacion de 4,1',6'-tricloro-4,1',6' tridesoxigalactosacarosa
HRPK20000092B1 (en) Polymorphic modifications of 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazole-carboxylic acid and processes for the preparation thereof
AU2732395A (en) A cathode material for lithium secondary batteries and a process and a precursor material for the production thereof
CA2429228A1 (en) Improved sucralose composition and process for the crystallization thereof
CA2171435A1 (en) Effervescent granulated material and method for its preparation
WO1997013774A3 (fr) Nouveaux derives de la 5-o-desosaminyl 6-o-methyl erythronolide a, leur procede de preparation et leur application a la preparation de produits biologiquement actifs
AU7829787A (en) Naphthalene and indan derivatives
MY110352A (en) Process for preparing 4-demethoxydaunorubicin.
IE800208L (en) Production of isosorbide-5-nitrate
CA2089193A1 (en) Diacetyl production
EP1195356A4 (en) SHEET METAL TITANATE COMPOSITE AND METHOD FOR THE PRODUCTION THEREOF
IE780504L (en) Preparing 5-(4-hydroxyphenyl) hydantoin
EP0922704A4 (en) METHOD FOR THE PRODUCTION AND INTERMEDIATE OF 2- (10,11-DIHYDRO-10-OXODIBENZO [B, F] THIEPIN-2-YL) -PROPIONIC ACID
CA2297112A1 (en) Dicyclanil polymorphs and hydrates and their preparation
CA2252952A1 (en) Substituted aminomethylphenylsulphonylureas, their preparation, and their use as herbicides and plant growth regulators
Zachwieja Single Crystal Growth and Structure Refinement of NaAu sub 2--a New Synthesis Method for Alkali Metal--Gold Compounds
Albastroiu Contributions to the improvement of petroleum coke calcination technology
JPS5435197A (en) Preparation of zinc hydroxide platy crystals
Maurer et al. Process for producing hydroxylapatite
Duboff et al. Diacetyl production
EP0400558A3 (en) Phenylacetic acid derivative
Xue et al. Crystal structure of EuAu sub 2 Al sub 2
Stepien-Damm et al. Crystal structure of TbCoSi

Legal Events

Date Code Title Description
A1OB Publication of a patent application
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
B1PR Patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20080908

Year of fee payment: 11

PBON Lapse due to non-payment of renewal fee

Effective date: 20091003